Typically, compared with patients with a low TGFβ-ALK5 signature, cancer patients with an increased TGFβ-ALK5 signature exhibit a noticeable decrease in responsiveness to immune checkpoint inhibitors due to immune evasion and immune exclusion [21, 22]. Here, TGFB1 is linked to cancer.